The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus after the company posted Q2 2026 group revenue of US$247 million, up 21% on the prior year, and reaffirmed its full-year revenue guidance.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- Q2 2026 group revenue: US$247 million, up 21% year-over-year and 7% quarter-on-quarter
- Precision Medicine revenue: US$202 million, up 30% year-over-year and 9% quarter-on-quarter
- TMS revenue: US$45 million
- FY 2026 revenue and other income expected to exceed US$1 billion, tracking towards the upper end of guidance (US$950–970 million plus US$40 million Regeneron income)
- R&D expenditure guidance updated to US$230–270 million, reflecting increased investment capacity
- Initial non-refundable payment of US$40 million received from strategic partner Regeneron
What else do investors need to know?
Telix Pharmaceuticals continues to make progress across both its Precision Medicine and Therapeutics businesses. The company achieved a key regulatory milestone for the global Phase 3 trial of TLX591-Tx in prostate cancer, with FDA alignment allowing the study to advance to Part 2 in the US. Enrolment is ongoing in several regions, including Australia and China.
In its Precision Medicine business, Telix is nearing full patient enrolment in the BiPASS Phase 3 study for initial prostate cancer diagnosis, and has completed enrolling for its Phase 3 registrational study in Japan for Illuccix. The company is also progressing new regulatory filings and expanding its manufacturing footprint with new facilities in Melbourne, Brussels, and Yokohama.
Telix finalised a major strategic collaboration with Regeneron to develop radiopharmaceutical therapies, receiving an upfront payment and creating a strong platform for future oncology programs. The company also refinanced existing convertible bonds, boosting its capital flexibility.
What did Telix Pharmaceuticals management say?
Dr. Christian Behrenbruch, Managing Director and Group CEO, said:
We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value
What's next for Telix Pharmaceuticals?
Looking ahead, Telix expects FY 2026 revenue and other income to top US$1 billion, and is allocating additional funds to R&D to support the expansion of key clinical programs. Progress in product development, regulatory filings, and the new Regeneron partnership are expected to underpin further growth.
Management flagged ongoing milestones for pivotal clinical trials in both the Therapeutics and Precision Medicine businesses, as well as continued global geographic expansion. The company's strengthened capital position will support investment in its late-stage pipeline and manufacturing capability, with a focus on bringing new therapies to market.
Telix Pharmaceuticals share price snapshot
Over the past 12 months, Telix shares have declined 40%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 1% over the same period.
